Global Cellular Human Tissue-engineered Skin Substitute 麻豆原创 Growth 2024-2030

Publication ID:

LPI08246938

Publication Date:

August 22, 2024

Pages:

137

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Cellular Human Tissue-engineered Skin Substitute market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
The 鈥淐ellular Human Tissue-engineered Skin Substitute Industry Forecast鈥� looks at past sales and reviews total world Cellular Human Tissue-engineered Skin Substitute sales in 2023, providing a comprehensive analysis by region and market sector of projected Cellular Human Tissue-engineered Skin Substitute sales for 2024 through 2030. With Cellular Human Tissue-engineered Skin Substitute sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cellular Human Tissue-engineered Skin Substitute industry.
This Insight Report provides a comprehensive analysis of the global Cellular Human Tissue-engineered Skin Substitute landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cellular Human Tissue-engineered Skin Substitute portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Cellular Human Tissue-engineered Skin Substitute market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cellular Human Tissue-engineered Skin Substitute and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cellular Human Tissue-engineered Skin Substitute.
United States market for Cellular Human Tissue-engineered Skin Substitute is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Cellular Human Tissue-engineered Skin Substitute is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Cellular Human Tissue-engineered Skin Substitute is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Cellular Human Tissue-engineered Skin Substitute players cover Allergan (AbbVie), AlloSource, Organogenesis, BD and Smith & Nephew, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Cellular Human Tissue-engineered Skin Substitute market by product type, application, key manufacturers and key regions and countries.
Segmentation by type
Cellular Allogeneic
Cellular Autologous
Others
Segmentation by application
Hospitals
Specialty Clinics
Wound Care Centers
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Allergan (AbbVie)
AlloSource
Organogenesis
BD
Smith & Nephew
Integra LifeSciences
Synthes (Johnson & Johnson)
Axogen
Vericel Corporation
LifeNet Health
MTF Biologics
Arthrex
Wright Medical Group NV (Stryker)
Cook Biotech Incorporated
Aroa Biosurgery
Surgalign Holdings
Key Questions Addressed in this Report
What is the 10-year outlook for the global Cellular Human Tissue-engineered Skin Substitute market?
What factors are driving Cellular Human Tissue-engineered Skin Substitute market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Cellular Human Tissue-engineered Skin Substitute market opportunities vary by end market size?
How does Cellular Human Tissue-engineered Skin Substitute break out type, application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Cellular Human Tissue-engineered Skin Substitute Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Cellular Human Tissue-engineered Skin Substitute by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Cellular Human Tissue-engineered Skin Substitute by Country/Region, 2019, 2023 & 2030
2.2 Cellular Human Tissue-engineered Skin Substitute Segment by Type
2.2.1 Cellular Allogeneic
2.2.2 Cellular Autologous
2.2.3 Others
2.3 Cellular Human Tissue-engineered Skin Substitute Sales by Type
2.3.1 Global Cellular Human Tissue-engineered Skin Substitute Sales 麻豆原创 Share by Type (2019-2024)
2.3.2 Global Cellular Human Tissue-engineered Skin Substitute Revenue and 麻豆原创 Share by Type (2019-2024)
2.3.3 Global Cellular Human Tissue-engineered Skin Substitute Sale Price by Type (2019-2024)
2.4 Cellular Human Tissue-engineered Skin Substitute Segment by Application
2.4.1 Hospitals
2.4.2 Specialty Clinics
2.4.3 Wound Care Centers
2.5 Cellular Human Tissue-engineered Skin Substitute Sales by Application
2.5.1 Global Cellular Human Tissue-engineered Skin Substitute Sale 麻豆原创 Share by Application (2019-2024)
2.5.2 Global Cellular Human Tissue-engineered Skin Substitute Revenue and 麻豆原创 Share by Application (2019-2024)
2.5.3 Global Cellular Human Tissue-engineered Skin Substitute Sale Price by Application (2019-2024)
3 Global Cellular Human Tissue-engineered Skin Substitute by Company
3.1 Global Cellular Human Tissue-engineered Skin Substitute Breakdown Data by Company
3.1.1 Global Cellular Human Tissue-engineered Skin Substitute Annual Sales by Company (2019-2024)
3.1.2 Global Cellular Human Tissue-engineered Skin Substitute Sales 麻豆原创 Share by Company (2019-2024)
3.2 Global Cellular Human Tissue-engineered Skin Substitute Annual Revenue by Company (2019-2024)
3.2.1 Global Cellular Human Tissue-engineered Skin Substitute Revenue by Company (2019-2024)
3.2.2 Global Cellular Human Tissue-engineered Skin Substitute Revenue 麻豆原创 Share by Company (2019-2024)
3.3 Global Cellular Human Tissue-engineered Skin Substitute Sale Price by Company
3.4 Key Manufacturers Cellular Human Tissue-engineered Skin Substitute Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Cellular Human Tissue-engineered Skin Substitute Product Location Distribution
3.4.2 Players Cellular Human Tissue-engineered Skin Substitute Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Cellular Human Tissue-engineered Skin Substitute by Geographic Region
4.1 World Historic Cellular Human Tissue-engineered Skin Substitute 麻豆原创 Size by Geographic Region (2019-2024)
4.1.1 Global Cellular Human Tissue-engineered Skin Substitute Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Cellular Human Tissue-engineered Skin Substitute Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Cellular Human Tissue-engineered Skin Substitute 麻豆原创 Size by Country/Region (2019-2024)
4.2.1 Global Cellular Human Tissue-engineered Skin Substitute Annual Sales by Country/Region (2019-2024)
4.2.2 Global Cellular Human Tissue-engineered Skin Substitute Annual Revenue by Country/Region (2019-2024)
4.3 Americas Cellular Human Tissue-engineered Skin Substitute Sales Growth
4.4 APAC Cellular Human Tissue-engineered Skin Substitute Sales Growth
4.5 Europe Cellular Human Tissue-engineered Skin Substitute Sales Growth
4.6 Middle East & Africa Cellular Human Tissue-engineered Skin Substitute Sales Growth
5 Americas
5.1 Americas Cellular Human Tissue-engineered Skin Substitute Sales by Country
5.1.1 Americas Cellular Human Tissue-engineered Skin Substitute Sales by Country (2019-2024)
5.1.2 Americas Cellular Human Tissue-engineered Skin Substitute Revenue by Country (2019-2024)
5.2 Americas Cellular Human Tissue-engineered Skin Substitute Sales by Type
5.3 Americas Cellular Human Tissue-engineered Skin Substitute Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Cellular Human Tissue-engineered Skin Substitute Sales by Region
6.1.1 APAC Cellular Human Tissue-engineered Skin Substitute Sales by Region (2019-2024)
6.1.2 APAC Cellular Human Tissue-engineered Skin Substitute Revenue by Region (2019-2024)
6.2 APAC Cellular Human Tissue-engineered Skin Substitute Sales by Type
6.3 APAC Cellular Human Tissue-engineered Skin Substitute Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Cellular Human Tissue-engineered Skin Substitute by Country
7.1.1 Europe Cellular Human Tissue-engineered Skin Substitute Sales by Country (2019-2024)
7.1.2 Europe Cellular Human Tissue-engineered Skin Substitute Revenue by Country (2019-2024)
7.2 Europe Cellular Human Tissue-engineered Skin Substitute Sales by Type
7.3 Europe Cellular Human Tissue-engineered Skin Substitute Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Cellular Human Tissue-engineered Skin Substitute by Country
8.1.1 Middle East & Africa Cellular Human Tissue-engineered Skin Substitute Sales by Country (2019-2024)
8.1.2 Middle East & Africa Cellular Human Tissue-engineered Skin Substitute Revenue by Country (2019-2024)
8.2 Middle East & Africa Cellular Human Tissue-engineered Skin Substitute Sales by Type
8.3 Middle East & Africa Cellular Human Tissue-engineered Skin Substitute Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Cellular Human Tissue-engineered Skin Substitute
10.3 Manufacturing Process Analysis of Cellular Human Tissue-engineered Skin Substitute
10.4 Industry Chain Structure of Cellular Human Tissue-engineered Skin Substitute
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Cellular Human Tissue-engineered Skin Substitute Distributors
11.3 Cellular Human Tissue-engineered Skin Substitute Customer
12 World Forecast Review for Cellular Human Tissue-engineered Skin Substitute by Geographic Region
12.1 Global Cellular Human Tissue-engineered Skin Substitute 麻豆原创 Size Forecast by Region
12.1.1 Global Cellular Human Tissue-engineered Skin Substitute Forecast by Region (2025-2030)
12.1.2 Global Cellular Human Tissue-engineered Skin Substitute Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Cellular Human Tissue-engineered Skin Substitute Forecast by Type
12.7 Global Cellular Human Tissue-engineered Skin Substitute Forecast by Application
13 Key Players Analysis
13.1 Allergan (AbbVie)
13.1.1 Allergan (AbbVie) Company Information
13.1.2 Allergan (AbbVie) Cellular Human Tissue-engineered Skin Substitute Product Portfolios and Specifications
13.1.3 Allergan (AbbVie) Cellular Human Tissue-engineered Skin Substitute Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Allergan (AbbVie) Main Business Overview
13.1.5 Allergan (AbbVie) Latest Developments
13.2 AlloSource
13.2.1 AlloSource Company Information
13.2.2 AlloSource Cellular Human Tissue-engineered Skin Substitute Product Portfolios and Specifications
13.2.3 AlloSource Cellular Human Tissue-engineered Skin Substitute Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 AlloSource Main Business Overview
13.2.5 AlloSource Latest Developments
13.3 Organogenesis
13.3.1 Organogenesis Company Information
13.3.2 Organogenesis Cellular Human Tissue-engineered Skin Substitute Product Portfolios and Specifications
13.3.3 Organogenesis Cellular Human Tissue-engineered Skin Substitute Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Organogenesis Main Business Overview
13.3.5 Organogenesis Latest Developments
13.4 BD
13.4.1 BD Company Information
13.4.2 BD Cellular Human Tissue-engineered Skin Substitute Product Portfolios and Specifications
13.4.3 BD Cellular Human Tissue-engineered Skin Substitute Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 BD Main Business Overview
13.4.5 BD Latest Developments
13.5 Smith & Nephew
13.5.1 Smith & Nephew Company Information
13.5.2 Smith & Nephew Cellular Human Tissue-engineered Skin Substitute Product Portfolios and Specifications
13.5.3 Smith & Nephew Cellular Human Tissue-engineered Skin Substitute Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Smith & Nephew Main Business Overview
13.5.5 Smith & Nephew Latest Developments
13.6 Integra LifeSciences
13.6.1 Integra LifeSciences Company Information
13.6.2 Integra LifeSciences Cellular Human Tissue-engineered Skin Substitute Product Portfolios and Specifications
13.6.3 Integra LifeSciences Cellular Human Tissue-engineered Skin Substitute Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Integra LifeSciences Main Business Overview
13.6.5 Integra LifeSciences Latest Developments
13.7 Synthes (Johnson & Johnson)
13.7.1 Synthes (Johnson & Johnson) Company Information
13.7.2 Synthes (Johnson & Johnson) Cellular Human Tissue-engineered Skin Substitute Product Portfolios and Specifications
13.7.3 Synthes (Johnson & Johnson) Cellular Human Tissue-engineered Skin Substitute Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Synthes (Johnson & Johnson) Main Business Overview
13.7.5 Synthes (Johnson & Johnson) Latest Developments
13.8 Axogen
13.8.1 Axogen Company Information
13.8.2 Axogen Cellular Human Tissue-engineered Skin Substitute Product Portfolios and Specifications
13.8.3 Axogen Cellular Human Tissue-engineered Skin Substitute Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Axogen Main Business Overview
13.8.5 Axogen Latest Developments
13.9 Vericel Corporation
13.9.1 Vericel Corporation Company Information
13.9.2 Vericel Corporation Cellular Human Tissue-engineered Skin Substitute Product Portfolios and Specifications
13.9.3 Vericel Corporation Cellular Human Tissue-engineered Skin Substitute Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Vericel Corporation Main Business Overview
13.9.5 Vericel Corporation Latest Developments
13.10 LifeNet Health
13.10.1 LifeNet Health Company Information
13.10.2 LifeNet Health Cellular Human Tissue-engineered Skin Substitute Product Portfolios and Specifications
13.10.3 LifeNet Health Cellular Human Tissue-engineered Skin Substitute Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 LifeNet Health Main Business Overview
13.10.5 LifeNet Health Latest Developments
13.11 MTF Biologics
13.11.1 MTF Biologics Company Information
13.11.2 MTF Biologics Cellular Human Tissue-engineered Skin Substitute Product Portfolios and Specifications
13.11.3 MTF Biologics Cellular Human Tissue-engineered Skin Substitute Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 MTF Biologics Main Business Overview
13.11.5 MTF Biologics Latest Developments
13.12 Arthrex
13.12.1 Arthrex Company Information
13.12.2 Arthrex Cellular Human Tissue-engineered Skin Substitute Product Portfolios and Specifications
13.12.3 Arthrex Cellular Human Tissue-engineered Skin Substitute Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Arthrex Main Business Overview
13.12.5 Arthrex Latest Developments
13.13 Wright Medical Group NV (Stryker)
13.13.1 Wright Medical Group NV (Stryker) Company Information
13.13.2 Wright Medical Group NV (Stryker) Cellular Human Tissue-engineered Skin Substitute Product Portfolios and Specifications
13.13.3 Wright Medical Group NV (Stryker) Cellular Human Tissue-engineered Skin Substitute Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Wright Medical Group NV (Stryker) Main Business Overview
13.13.5 Wright Medical Group NV (Stryker) Latest Developments
13.14 Cook Biotech Incorporated
13.14.1 Cook Biotech Incorporated Company Information
13.14.2 Cook Biotech Incorporated Cellular Human Tissue-engineered Skin Substitute Product Portfolios and Specifications
13.14.3 Cook Biotech Incorporated Cellular Human Tissue-engineered Skin Substitute Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Cook Biotech Incorporated Main Business Overview
13.14.5 Cook Biotech Incorporated Latest Developments
13.15 Aroa Biosurgery
13.15.1 Aroa Biosurgery Company Information
13.15.2 Aroa Biosurgery Cellular Human Tissue-engineered Skin Substitute Product Portfolios and Specifications
13.15.3 Aroa Biosurgery Cellular Human Tissue-engineered Skin Substitute Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 Aroa Biosurgery Main Business Overview
13.15.5 Aroa Biosurgery Latest Developments
13.16 Surgalign Holdings
13.16.1 Surgalign Holdings Company Information
13.16.2 Surgalign Holdings Cellular Human Tissue-engineered Skin Substitute Product Portfolios and Specifications
13.16.3 Surgalign Holdings Cellular Human Tissue-engineered Skin Substitute Sales, Revenue, Price and Gross Margin (2019-2024)
13.16.4 Surgalign Holdings Main Business Overview
13.16.5 Surgalign Holdings Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.